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ABSTRACT
Background: An antibody panel is needed to definitively differentiate between adenocarcinoma (AC)
and squamous cell carcinoma (SCC) in order to meet more stringent requirements for the histologic
classification of lung cancers. Staining of desmosomal plaque-related proteins may be useful in the
diagnosis of lung SCC.
Materials and methods: We compared the usefulness of six conventional (CK5/6, p40, p63, CK7, TTF1,
and Napsin A) and three novel (PKP1, KRT15, and DSG3) markers to distinguish between lung SCC and
AC in 85 small biopsy specimens (41 ACs and 44 SCCs). Correlations were examined between expres-
sion of the markers and patients’ histologic and clinical data.
Results: The specificity for SCC of membrane staining for PKP1, KRT15, and DSG3 was 97.4%, 94.6%,
and 100%, respectively, and it was 100% when the markers were used together and in combination
with the conventional markers (AUCs of 0.7619 for Panel 1 SCC, 0.7375 for Panel 2 SCC, 0.8552 for
Panel 1 AC, and 0.8088 for Panel 2 AC). In a stepwise multivariate logistic regression model, the com-
bination of CK5/6, p63, and PKP1 in membrane was the optimal panel to differentiate between SCC
and AC, with a percentage correct classification of 96.2% overall (94.6% of ACs and 97.6% of SCCs).
PKP1 and DSG3 are related to the prognosis.
Conclusions: PKP1, KRT15, and DSG3 are highly specific for SCC, but they were more useful to differ-
entiate between SCC and AC when used together and in combination with conventional markers.
PKP1 and DSG3 expressions may have prognostic value.
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Lung cancer is one of the most widely prevalent cancers and
has the highest cancer-related mortality rate worldwide (1),
with small-cell lung cancer (SCLC; 15%) and non-small-cell
lung cancer (NSCLC; 85%) being the two main histological
types. NSCLC can be divided into three major histological
subtypes: squamous cell carcinoma (SCC), adenocarcinoma
(AC), and large-cell lung cancer. AC and SCC account for the
vast majority of NSCLC cases. SCCs usually arise in a main or
lobar bronchus and are therefore more frequently localized
centrally in the lung, while the most common localization of
invasive AC is the lung periphery (2). Accurate histological
subclassification of NSCLCs is crucial, because the therapeutic
approach depends on their histological type. Therefore, the
latest revision of the World Health Organization (WHO)
classification of lung neoplasms includes guidelines for the
terminology and procedure to be followed in order to clas-
sify pulmonary neoplasms in small biopsies, recommending
immunohistochemical analysis when available (2,3). For
instance, epidermal growth factor receptor (EGFR) inhibitors
and the anti-folate agent pemetrexed are recommended for
the treatment of AC but not SCC (4,5). Moreover, EGFR muta-
tions and gene fusions including ALK and ROS1 are almost
exclusively present in non-squamous cancer forms. Further,
patients with AC who possess the fusion gene EML4–ALK
(echinoderm microtubule-associated protein-like 4–anaplastic
lymphoma kinase) or EGFR gene-activating mutations can
respond to the respective tyrosine–kinase inhibitors (6,7).
Additionally, SCC patients should not be treated with the
anti-vascular endothelial growth factor agent bevacizumab,
which frequently produces lung haemorrhage (8). The
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identification of new therapeutic targets means that tissue
samples are used not only for diagnosis but also for immu-
nohistochemical staining and molecular testing in relation to
potential therapy (3). This is particularly challenging when
small biopsies or cytology smears are the only material avail-
able, as in 70% of lung cancer patients with advanced dis-
ease and inoperable neoplasms at diagnosis (3). These
challenges led to new classification proposals for non-resec-
tion specimens, biopsies, and cytology, including the ASLC/
ATS/ERS lung adenocarcinoma classification and the latest
revision of the WHO lung cancer classification, which include
the need for ancillary techniques such as immunohistochem-
istry (2,9). With the application of these techniques, the
accurate diagnosis of AC or SCC can improve from 50–70%
to above 90% (10,11). The search for novel markers to accur-
ately differentiate between AC and SCC is therefore of major
clinical relevance.
Desmosomes are cell structures specialized for focal cell-
to-cell adhesion that are localized in randomly arranged
spots on the lateral sides of plasma membranes. They play
an important role in providing strength to tissues under
mechanical stress, such as the cardiac muscle and epidermis.
Besides the constitutive desmosomal plaque proteins desmo-
plakin and plakoglobin, at least one of the three classical
members of the plakophilin (PKP) family is required to form
functional desmosomes (12–14). PKP1 is a major desmosomal
plaque component that recruits intermediate filaments to
sites of cell–cell contact via interaction with desmoplakin.
PKPs regulate cellular processes, including protein synthesis
and cell growth, proliferation, and migration, and they have
been implicated in tumour development (15–21).
Desmoglein 3 (DSG3) is one of seven desmosomal cadher-
ins. Desmosomal proteins act as tumour suppressors and are
downregulated in epithelial–mesenchymal transition and in
tumour cell invasion and metastasis. However, some studies
have shown the upregulation of several desmosomal compo-
nents in cancer, including DSG3, and overexpression of these
proteins has been related to the prognosis. Therefore,
desmosomal proteins can potentially serve as diagnostic and
prognostic markers (22). Keratin 15 (KRT15) is a type I keratin
protein present in the basal keratinocytes of stratified epithe-
lium. For this reason, it has been reported as a marker of
stem cells. However, several studies have demonstrated
KRT15 expression in differentiated cells (23). Our group previ-
ously reported that gene sequences corresponding to the
desmosomal plaque-related proteins PKP1, DSG3, and KRT15
were differentially expressed in primary AC and SCC of the
lung (24). Subsequently, we also described the localization of
PKP1 in nucleus, cytoplasm, and cell membrane in tumours
and proposed the utilization of these proteins as immunohis-
tochemical markers (25).
Immunohistochemistry is widely used for the subtyping of
lung carcinomas. Thyroid transcription factor 1 (TTF1) (26)
and Napsin A (27) are considered the most useful markers
for AC diagnosis, and evaluation of the former is considered
easier because it is a nuclear marker. Although cytokeratin 7
(CK7) has also been used as a marker of AC (28), its useful-
ness is not universally accepted (2). Cytokeratin 5/6 (CK5/6),
p63, and p40 are recommended markers for SCC (28,29),
while DSG3 and desmocollin 3 have also emerged as poten-
tial SCC markers, although their clinical value has yet to be
established (25,30,31). However, despite the efficacy of these
markers, numerous confirmed lung carcinoma cases are
either positive for both AC and SCC markers (double-posi-
tive) or negative for one or the other type of marker (32).
Given the more stringent requirements for the histologic
classification of lung cancers, an antibody panel is required
that definitively differentiates AC from SCC. A particular chal-
lenge is posed by poorly differentiated tumours and by sam-
ples with the technical artefacts frequently encountered in
small biopsy specimens, which are the only available tissue
samples from patients in advanced stages.
In this study, we compared the usefulness of six conven-
tional and three novel markers for the differential diagnosis
of lung SCC and AC in small biopsy specimens. We also
explored correlations between the expression of these
markers and the histologic and clinical data of the patients.
Materials and methods
Tumour tissues
Specimens used in this study were from 87 patients who
underwent surgical resection for lung cancer. All patients
were stages I (54 patients), II (20 patients), or III (10 patients),
except for three patients in stage IV, and were selected for
surgery with no previous chemotherapy or radiotherapy
treatments. Only cases in which the histological diagnosis of
the resected specimen was invasive AC or SCC were
included, representing the majority of the series (85
patients). The remaining two cases, which corresponded to
sarcomatoid carcinoma, were excluded from the study.
Histological diagnosis of the surgical specimens followed
the recommendations of the WHO 2015 classification (2),
based on morphology and ancillary techniques, mainly
immunohistochemistry, when needed. Therefore, the present
study included 85 samples from primary malignant lung neo-
plasms (41 ACs and 44 SCCs) in stage I (54 patients), stage II
(18 patients), stage III (10 patients), or stage IV (3 patients),
which were obtained by incisional biopsy of 0.4 cm during
tumour surgery. Samples were divided into two, and one
half was used for RNA extraction, the results of which have
previously been published (24). The other half was fixed in
buffered formalin and embedded in paraffin blocks, from
which 3–4-lm sections were cut for conventional haema-
toxylin and eosin staining.
The 85 incisional biopsies were analyzed by two patholo-
gists (authors MGM and MCM) and classified according to
the WHO 2015 classification (2), cataloguing those with kera-
tinization and/or intercellular bridges as SCCs and those with
glandular differentiation and/or mucin production as ACs,
including acinar, papillary, lepidic, or solid growth patterns.
In addition, SCCs were classified as well-differentiated if kera-
tinization and/or intercellular bridges were observed in more
than 75% of the tumour sample, moderately differentiated if
observed in 25–75%, and poorly differentiated if observed in
less than 25%. Likewise, ACs were subclassified as well-
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differentiated when glandules were formed in more than
75% of the tumour sample, moderately differentiated when
formed in 25–75%, and poorly differentiated when observed
in less than 25%. Diagnoses of the biopsy samples were
compared with the definitive diagnoses of the surgi-
cal specimens.
Before the study, all medical records and tumour sections
from surgical specimens were reviewed. Informed consent
was obtained from all participants. The study protocol com-
plied with the Helsinki Declaration of 1975 as revised in
1983. Written informed consent was obtained from all
patients for the study, which was approved by the Ethics
Committee of our Institution (Clinical Trial Committee of San
Cecilio University Hospital, Granada). Pathological evaluation
of resected specimens was carried out using the 1997 revi-
sion of the International System for Staging Lung Cancer (33)
and revised according to the most recent (7th) edition of the
tumour, node, and metastasis classification of the
International Union Against Cancer (UICC) staging system. All
specimens were primary tumours with no history of treat-
ment that could affect the immunohistochemical results.
Immunohistochemistry
Sections of 4-lm thickness were taken from the paraffin
blocks, mounted on pre-treated slices, and stained for PKP1
(rabbit polyclonal, HPA027221; Sigma, St Louis, MO, USA),
KRT15 (rabbit polyclonal, HPA024554; Sigma), and DSG3
(mouse monoclonal, NB100-1643; Abcam, Cambridge, UK).
Normal human skin was used as positive control. After test-
ing several dilutions, PKP1 and DSG3 were diluted at 1:200
and KRT15 at 1:500. Prediluted monoclonal antibodies from
Master Diagnostica were used for the remaining determina-
tions: TTF1 (000486QD, clone SPT24), Napsin A (001004QD,
clone BS10), CK7 (001004QD, clone OVTL 12/30), CK5/6
(000680QD, clone EP24/EP67/B22-18B231), p63 (000479QD
clone 4a4), and p40 (000686QD, clone ZR8).
Normal lung tissue was used as a positive control for
TTF1 and Napsin A, breast cancer for CK7, and skin SCC for
CK5/6, p63, and p40. As negative controls, the same positive
controls were used, replacing the primary antibody with PBS.
Immunohistochemical staining was carried out by auto-
matic immunostaining (LabVision Autostainer 480 s
Thermofisher) using the Master Polymer Plus Detection
System (MAD-000327QK Master Diagnostic) and following
the manufacturer’s instructions. Diaminobenzidine was used
as chromogen, and sections were counterstained with
haematoxylin. Immunohistochemical staining was evaluated
independently by two pathologists (authors MGM and MCM),
who assigned a score based on the extent and intensity of
immunoreactivity. Agreement between pathologists was
>90%, and any differences in interpreting results were
resolved by consensus. Staining for PKP1, CK15, and DSG3
was evaluated semiquantitatively in nucleus, cytoplasm, and
membrane as negative (0, <5% cells stained), positive 1þ
(6–25% cells stained), positive 2þ (26–50% cells stained), or
positive 3þ (>50% cells stained). Staining intensity at the
same localizations was scored semiquantitatively from 0 to 3.
Immunostaining results were scored as the sum of the extent
and intensity of immunoreactivity, considering a score 3
positive and a score <3 negative. Only cases with nuclear
staining were considered positive for TTF1, p63, and p40,
while those with cytoplasmic/membranous staining were
considered positive for CK5/6 and CK7, and those with char-
acteristic granular and cytoplasmic staining were considered
positive for Napsin.
Statistical analysis
IBM SPSS20 statistical package was used for data analyses
unless otherwise specified. The relationship of clinical-patho-
logical characteristics with marker expression was evaluated
using the chi-square (v2) or Fisher’s exact tests. Odds ratios
with 95% confidence intervals (CIs) were calculated for 2 2
tables. Accuracy measures were calculated for each marker
with the corresponding 95% CIs. p 0.05 was considered
statistically significant. Survival analyses were performed with
R 3.4.0 software, using the ‘survival’ (v2.42–3) and ‘survminer’
(v0.4.2) packages. Clinical information and normalized gene
expression data were downloaded from Firebrowse (v1.1.38;
http://firebrowse.org/) for the TCGA-LUSC project (n¼ 504).
Patients with SCC from the TCGA-LUSC cohort were divided
into two groups for analysis of the relationship between sur-
vival outcomes and gene expression: ‘high’ (above the
median for the specific gene) and ‘low’ (below the median).
Kaplan–Meier curves were plotted for the raw survival data,
and Cox proportional hazards models were then constructed,
accounting for tumour stage and for patient age and sex.
Results
Expression of conventional markers
We studied six well-documented markers conventionally con-
sidered of utility for the differential diagnosis of SCC and AC
and routinely used by many histopathology laboratories
(34–37). CK5/6, p40, and p63 are considered markers of SCC,
while CK7, TTF1, and Napsin A are considered markers of AC.
In our cohort of 85 patients, the most sensitive conventional
marker for AC was CK7 (97.6%, with 2.4% false negatives),
followed by Napsin A (80.5%, with 19.5% false negatives)
and TTF1 (75%, with 25% false negatives). However, the
most specific marker was TTF1 (97.7%), followed by Napsin A
(93.2%), and CK7 (56.8%).
The most sensitive conventional marker for SCC was p63
(95.5%), followed by CK5/6 (93.2%) and p40 (88.6%), whereas
p40 was the most specific (95.1%), followed by CK5/6
(92.7%) and p63 (85.4%). Other statistical analyses evaluating
agreement and reproducibility are displayed in Tables 1 and
2. Among the conventional markers for AC (CK7, TTF1, and
Napsin A) and SCC (CK5/6, p40, and p63) analyzed in our
cohort of patients, only TTF1 in AC and p40 in SCC were spe-
cific in 94% of the samples, with 94% true positives.
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Expression of novel SCC markers
We studied three novel markers for SCC (PKP1, KRT15, and
DSG3) that may contribute to the differential diagnosis of
SCC and AC, also analyzing their localization (nucleus, cyto-
plasm, or membrane). Immunohistochemical staining for
PKP1 was mainly detected in SCC, with a heterogeneous dis-
tribution and intensity among the different tumours ana-
lyzed, and in different areas of the same neoplasm. PKP1
most frequently stained cellular membranes, marking inter-
cellular junctions, followed by staining of the cytoplasm.
Membranous staining was mainly observed in well to moder-
ately differentiated areas of SCC. Nuclear staining was less
often observed and was more frequent in cells with a more
immature appearance (Figure 1). Membranous staining was
never observed in ACs, although focal staining in nucleus
and cytoplasm was occasionally observed (Figure 2). KRT15
was also mainly restricted to SCC (Figure 3), with variable
distribution and intensity among different SCCs and among
different areas of the same neoplasm. Staining in SCC was
also observed in better-differentiated areas, mainly in cell
membrane but also in cytoplasm. Nuclear staining was less
frequently observed than with PKP1 and was seen in occa-
sional cells with less-differentiated appearance (Figure 3). In
ACs, KRT15 was absent in cell membrane and only occasion-
ally present in a few cells localized in nucleus and cytoplasm.
Staining for DSG3 was not observed in ACs, with the
exception of only a few nuclei in a small number of cases. As
occurred with PKP1 and KRT15, DSG3 stained SCCs with
irregular distribution and was more often observed in cell
membranes of better-differentiated areas and to a lesser
degree in cytoplasms. Nuclear staining was much less fre-
quent and mainly observed in poorly differentiated areas
(Figure 4).
In our cohort, the most sensitive marker was PKP1 in
nucleus (86%), followed by KRT15 in membrane (75.6%) and
DSG3 in membrane (64.3%). However, DSG3 in membrane
was the most specific (100%), followed by PKP1 in mem-
brane (97.4%) and KRT15 in membrane (94.6%). Other statis-
tical analyses evaluating agreement and reproducibility are
displayed in Tables 2 and 3.
According to these results, membranous staining with the
novel markers (PKP1, KRT15, and DSG3) was specific for
94% of the SCC samples, obtaining 94% true positives in
our cohort of patients.
The antibodies were also tested in combination. For SCC
samples, membranous PKP1 staining showed a specificity of
97.4% and sensitivity of 76.7% and membranous DSG3 stain-
ing a specificity of 100% and sensitivity of 64.3% when sep-
arately evaluated. When considered together, membranous
staining with these two markers achieved a specificity of
100% (95% CI ¼ 90.6%–100.0%) but sensitivity of 52.4%
(95% CI ¼ 37.7%–66.6%). Positive TTF1 staining provided a
specificity of 97.7% and a sensitivity of 75% for AC. When all
three markers were considered together in Panel 1 SCC
(positive membrane staining for PKP1 and DSG3 and nega-
tive staining for TTF1), the specificity for SCC samples was
increased to 100.0% (95% CI ¼ 90.6%–100.0%), but the sensi-
tivity was 52.4% (95% CI ¼ 37.7%–66.6%), with an AUC of
0.7619. Membranous KRT15 staining yielded a specificity of
97.4% and a sensitivity of 75.6% for SCC samples, and
Napsin A staining a specificity of 93.2% and a sensitivity of
80.5% for AC samples when evaluated separately. When all
five markers were considered together in Panel 2 SCC (posi-
tive membranous staining for PKP1, DSG3, and KRT15 and
Table 1. Conventional marker expression. Sensitivity, specificity, percentage of true positives and percentage of true negatives, accuracy, Youden’s J statistic,
and positive and negative likelihood ratio values for staining with markers conventionally used for the differential diagnosis of adenocarcinoma (CK7, TTF1, and
Napsin A) and squamous cell carcinoma (CK5/6, p40, and p63).
Squamous cell carcinoma Adenocarcinoma
CK5/6 p40 p63 CK7 TTF1 Napsin A
Sensitivity (%) (positive/total)a 93.2 (41/44) 88.6 (39/44) 95.5 (42/44) 97.6 (40/41) 75 (30/40) 80.5 (33/41)
Specificity (%) (positive/total)b 92.7 (38/41) 95.1 (39/41) 85.4 (35/41) 56.8 (25/44) 97.7 (43/44) 93.2 (41/44)
PTP (%) (positive/total)c 93.2 (41/44) 95.1 (39/41) 87.5 (42/48) 67.8 (40/59) 96.8 (30/31) 91.7 (33/36)
PTN (%) (positive/total)d 92.7 (38/41) 88.6 (39/44) 94.6 (35/37) 96.2 (25/26) 81.1 (43/53) 83.7 (41/49)
Accuracy (%) (positive/total)e 92.9 (79/85) 91.8 (78/85) 90.6 (77/85) 76.5 (65/85) 86.9 (73/84) 87.1 (74/85)
Youden’s J statisticf 0.85 0.84 0.81 0.54 0.73 0.74
LRþg 12.64 18.08 6.54 2.26 32.61 11.84





eAccuracy¼ (TPþ TN)/(TPþ FPþ FNþ TN).
fYouden’s J statistic ¼ Sensitivityþ Specificity-1.
gPositive LR (LRþ)¼ Sensitivity/(1-Specificity).
hNegative LR (LR-)¼ (1-Sensitivity)/Specificity.
FN: false negatives; FP: false positives; LR: likelihood ratio; PTN: percentage of true negatives; PTP: percentage of true positives; TN: true negatives; TP:
true positives.





95% Asymptotic confidence interval
Lower limit Upper limit
PKP1_mb 0.861 0.000 0.773 0.950
DSG3_mb 0.813 0.000 0.712 0.913
KRT15_mb 0.861 0.000 0.773 0.949
TTF1 0.869 0.000 0.784 0.954
Napsin A 0.887 0.000 0.808 0.966
CK7 0.863 0.000 0.779 0.946
p63 0.965 0.000 0.923 1.000
CK5/6 0.960 0.000 0.914 1.000
p40 0.938 0.000 0.880 0.996
AUC: area under the curve.
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Figure 1. Immunohistochemical staining of PKP1 in SCC. (A) Predominant staining in cell membrane a (40). (B) Positivity in membrane and cytoplasm. Note
weak staining in less differentiated area (bottom left) (20). (C) Nuclear staining (40).
Figure 2. Immunohistochemical staining of PKP1 in AC. (A and B) Weak cytoplasmic and nuclear staining (40). (C) Poorly differentiated AC with completely nega-
tive staining (10).
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Figure 3. Immunohistochemistry for KRT15 in SCC. (A) Extensive positivity in well differentiated SCC in cell membranes (20). (B) Poorly differentiated area with
focal membranous staining (20). (C) Area with predominant cytoplasmic staining (60). (D) Poorly differentiated SCC showing some nuclei with faint staining
(arrows). Note negativity in stromal cells (arrow heads) (20).
Figure 4. Immunohistochemical staining of DSG3 in SCC. (A) Well differentiated SCC with intense positivity mainly in cell membranes (40). (B) More heteroge-
neous staining in cell membranes and some cytoplasms (20). (C) Faint cytoplasmic/nuclear staining in poorly differentiated area (40).
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negative staining for TTF1 and Napsin A), the specificity for
SCC samples was increased to 100.0% (95% CI¼
89.6%–100.0%), but the sensitivity was 47.5% (95%
CI¼ 32.9%–62.5%), with an AUC of 0.7375. For AC samples,
the combined evaluation of negative membranous staining
for PKP1 and DSG3 and positive TTF1, in Panel 1 AC,
increased the specificity for AC samples to 100.0% (95% CI¼
91.6%–100.0%), but the sensitivity was 24.3% (95%
CI¼ 13.4%–40.1%), with an AUC of 0.8552. When negative
membranous staining for PKP1, DSG3, and KRT15 and posi-
tive staining for TTF1 and Napsin A were considered
together in Panel 2 AC, the specificity for AC samples
increased to 100.0% (95% CI ¼ 91.2%–100.0%), and the sen-
sitivity was 63.6% (95% CI ¼ 46.6–77.8%), with an AUC of
0.8088 (Table 4).
ROC curve analysis
The area under the ROC curve (or AUC) represents an opti-
mal summary statistic for comparing the sensitivity and spe-
cificity of the nine markers (CK5/6, p40, p63, CK7, TTF1,
Napsin A, PKP1, KRT15, and DSG3). For the cohort of 85 pri-
mary malignant lung neoplasms (41 ACs and 44 SCCs),
including all histological grades, p63 (0.965) had the largest
AUC, followed by CK5/6 (0.960), and p40 (0.938), with AUC
values >0.9, while AUC values for the remaining markers
were between 0.8 and 0.9. AUC values are displayed in
Table 2.
Stepwise multivariate logistic regression model
A stepwise multivariate logistic regression model was con-
structed to determine the optimal immunohistochemical
marker panel for differentiating between SCC and AC. The
best result included the combination of markers CK5/6, p63,
and PKP1 in membrane, giving a percentage correct classifi-
cation of 96.2% overall (94.6% of ACs and 97.6% of SCCs).
Expression of novel SCC markers in relation to survival
Data on 80 patients were available for this analysis. The
Kaplan–Meier survival curve depicted in Figure 5(A) shows a
relationship between positive PKP1 staining and longer sur-
vival, although the difference was not statistically significant
(log-rank p¼ 0.19), possibly due to the limited sample size.
There was also a non-significant trend for longer survival in
SCC versus AC patients (log-rank p¼ 0.47). In order to over-
come this sample size limitation and remove tumour subtype
as a confounder, we also studied 495 patients in the TCGA-
LUSC cohort (The Cancer Genome Atlas) for whom survival
and gene expression data were available (Supplemental
Table 3. Expression of novel SCC markers. Sensitivity, specificity, percentage of true positives and percentage of true negatives, accuracy, Youden’s J statistic,
and positive and negative likelihood ratio values for PKP1, KRT15, and DSG3 staining according to their nuclear, cytoplasmic, or membranous localization.
PKP1 KRT15 DSG3
Nucleus Cytoplasm Membrane Nucleus Cytoplasm Membrane Nucleus Cytoplasm Membrane
Sensitivity (%)
(positive/total)a
72.1 (31/43) 86 (37/43) 76.7 (33/43) 19.5 (8/41) 73.2 (30/41) 75.6 (31/41) 16.7 (7/42) 61.9 (26/42) 64.3 (27/42)
Specificity (%)
(positive/total)b
92.3 (36/39) 82.1 (32/39) 97.4 (38/39) 73 (27/37) 94.6 (35/37) 94.6 (35/37) 89.7 (35/39) 94.9 (37/39) 100 (39/39)
PTP (%)
(positive/total)c
91.2 (31/34) 84.1 (37/44) 97.1 (33/34) 44.4 (8/18) 93.8 (30/32) 93.9 (31/33) 63.6 (7/11) 92.9 (26/28) 100 (27/27)
PTN (%)
(positive/total)d
75 (36/48) 84.2 (32/38) 79.2 (38/48) 45 (27/60) 76.1 (35/46) 77.8 (35/45) 50 (35/70) 69.8 (37/53) 72.2 (39/54)
Accuracy (%)
(positive/total)e
81.7 (67/82) 84.1 (69/82) 86.6 (71/82) 44.9 (35/78) 83.3 (65/78) 84.6 (66/78) 51.9 (42/81) 77.8 (63/81) 81.5 (66/81)
Youden’s J statisticf 0.64 0.68 0.74 0.08 0.68 0.70 0.06 0.57 0.643
LRþg 9.36 4.80 29.50 0.72 13.56 14.00 1.62 12.14 –





eAccuracy¼ (TPþ TN)/(TPþ FPþ FNþ TN).
fYouden’s J statistic ¼ Sensitivityþ Specificity-1.
gPositive LR (LRþ)¼ Sensitivity/(1-Specificity).
hNegative LR (LR-)¼ (1-Sensitivity)/Specificity.
FN: false negatives; FP: false positives; LR: likelihood ratio; PTN: percentage of true negatives; PTP: percentage of true positives; TN: true negatives; TP:
true positives.
Table 4. Combination of antibodies useful for diagnosis of SCC and AC.
Specificity Sensitivity AUC
Squamous cell carcinoma
Panel 1 SCC: PKP1mþ/DSG3mþ/TTF1- 100% 52.4% 0.7619
Panel 2 SCC: PKP1mþ/DSG3mþ/KRT15mþ/TTF1-/Napsin A- 100% 47.5% 0.7375
Adenocarcinoma
Panel 1 AC: PKP1m-/DSG3-/TTF1þ 100% 24.3% 0.8552
Panel 2 AC: PKP1m-/DSG3m-/KRT15m-/TTF1þ/Napsin Aþ 100% 63.6% 0.8088
AUC: area under the curve.
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Table 1, available online). In this cohort, a significant relation-
ship was found between higher PKP1 expression and better
overall survival (Figure 5(B)), obtaining a hazard ratio of
0.951 (95% CI ¼ 0.907–0.997; p¼ 0.036) in a Cox proportional
hazards model after adjusting for confounding variables.
We also performed survival analyses for all conventional
and novel SCC biomarkers in the TCGA cohort under the
same conditions as the PKP1 analysis. For the univariate anal-
yses, we stratified the patients as ‘high’ or ‘low’ for each
marker based on the expression being above or below the
median value, and we plotted Kaplan–Meier curves
(Supplemental Figures 1 and 2, available online). In the
multivariate analyses, we applied Cox proportional hazard
models for each marker, accounting for patient age, sex, and
tumour stage, in order to assess the relationship of expres-
sion at mRNA level with patient survival.
In the multivariate analyses, the high expression of three
SCC markers was associated with better survival: p63
(p¼ 0.007, HR ¼ 0.93 [0.88–0.98]), PKP1 (p¼ 0.036, HR ¼ 0.95
[0.91–1.0], as already noted), and CK5 (p¼ 0.018, HR ¼ 0.95
[0.91–0.99]). In addition, the association of DSG3 with survival
was close to statistical significance (p¼ 0.054, HR ¼ 0.96
[0.93–1.0]). Expression of KRT15 or p40 at the mRNA level
was not associated with patient survival.
Discussion
In this study, we selected three novel markers (PKP1, KRT15,
and DSG3) for a detailed evaluation and compared them
with six conventional markers that are well described in the
literature and are routinely used by many histopathology
laboratories (34–37). Given that a very high proportion (up
to 70%) of lung carcinomas are unresectable at their diagno-
sis (3), the biopsy sample is often the only available material
for a correct subtyping of the neoplasm, and the present
study focussed on small incisional biopsies taken during
surgery. The precise subtyping of NSCLCs is essential to
select the appropriate therapeutic approach. It is now recom-
mended to complement the morphological criteria estab-
lished by the WHO (2) with histochemical (e.g. mucin
staining) and immunohistochemical techniques alongside
molecular tests, whenever possible, especially for poorly dif-
ferentiated tumours and for the analysis of small biopsy sam-
ples (38). In many histopathology laboratories, small biopsies
are routinely subtyped using the combination of an AC
marker (TTF1) and an SCC marker (p63 or p40) (38–40).
However, there are several pitfalls in the differential diagno-
sis between SCC and AC by immunohistochemistry. For
instance, the most widely used clones of TTF1 monoclonal
antibodies are 8G7G3/1 and SPT24, which have been
reported to have different sensitivities and specificities, with
8G7G3/1 being more specific and SPT24 more sensitive (41).
Among SCC markers, p40 is considered the most specific but
can be positive in 3% of ACs (42).
Studies in whole-tissue sections indicate that SCCs have a
relatively precise immunophenotype, i.e. negativity for TTF1
and positivity for p63, CK5/6, and 34bE12. In contrast, ACs
are much more heterogeneous, and only diffuse positivity for
TTF1 is considered characteristic, given that a proportion of
ACs also express markers considered typical of SCCs. Hence,
albeit useful, no SCC marker is wholly specific (43).
According to the present results, among the expressions
of the conventional markers CK7, TTF1, and Napsin A, charac-
teristic of AC, and CK5/6, p40, and p63, characteristic of SCC,
only TTF1 in AC and p40 in SCC were specific in 94% of
samples in the present cohort, with 94% true positives.
Membrane staining with the novel markers (PKP1, KRT15,
and DSG3) was specific for 94% of the SCC samples, with
94% true positives in the present cohort. The antibody
panel studied was most effective for the classification of SCC
and AC when the antibodies were applied successively in a
stepwise manner. We found that the specificity was higher
Figure 5. Survival analyses for PKP1 expression in lung cancer patients. (A) Survival analysis of our cohort of 38 SCC and 40 AC patients, classified as ‘PKP1-nega-
tive’ or ‘PKP1-positive’ according to the immunohistochemical staining of PKP1. (B) Survival analysis of the TCGA-LUSC cohort (n¼ 495 SCC patients), classified
according to their RNA-Seq-measured PKP1 RNA level as ‘PKP1 low’ (below median value) or ‘PKP1 high’ (above median value).
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(100%) when the antibodies were used in combination rather
than individually. For SCC, the most effective panels were:
Panel 1 SCC (positive staining of membrane for PKP1 and
DSG3 and negative staining for TTF1; AUC of 0.7619) and
Panel 2 SCC (positive staining of membrane for PKP1, DSG3,
and KRT15 and negative staining for TTF1 and Napsin A;
AUC of 0.7375). For AC, the most effective panels were:
Panel 1 AC (negative staining of membrane for PKP1 and
DSG3 and positive staining for TTF1; AUC of 0.8552) and
Panel 2 AC (negative staining of membrane for PKP1, DSG3,
and KRT15 and positive staining for TTF1 and Napsin A; AUC
of 0.8088).
The novel markers described here showed a heteroge-
neous staining of SCC, which was observed in the mem-
branes and cytoplasm of more differentiated cells, marking
the intercellular junctions, with staining of nuclei more fre-
quently detected in areas of more immature appearance. In
AC samples, focal staining with these novel markers was
detected in nucleus and cytoplasm, but never in membrane.
In addition to their role in cell adhesion, plakophilins, includ-
ing PKP1, have been reported to localize to the cytoplasm
and nucleus, where they are thought to have several func-
tions that are not completely understood (18). This explains
the nuclear and cytoplasmic positivity observed, mainly in
SCC in our series. In a few cases and in a few cells, we have
also seen occasional nuclear staining for CKT15 and DSG3.
Although nuclear localization of CKT15 and DSG3 has not
been reported (22,23) and non-specific staining cannot be
ruled out, it has been shown that several cytoskeletal pro-
teins, formerly thought to be exclusively cytoplasmic, and
including some keratins (keratins 7, 8, 17, and 18), are com-
ponents of the nuclear matrix, where they may have multiple
functions. Some studies of skin and cervical tumours indi-
cated that keratin 17 has a role in the cell cycle and in gene
expression regulation (44). These data and the fact that
KRT15 and DSG3 are not routinely used in most laboratories
prompted our assessment of nuclear staining. Further investi-
gation is warranted to explore the significance of
our findings.
In our cohort of patients, the relationship of PKP1 staining
with better survival of SCC and AC patients did not reach
statistical significance; however, we were able to confirm the
relationship between high PKP1 mRNA expression and better
overall survival in an additional analysis of 495 SCC patients
from TCGA. In addition, our TCGA analysis revealed a close-
to-significant association between high DSG3 mRNA expres-
sion and improved overall survival. This agrees with previous
reports that associated positive DSG3 staining with longer
survival in lung cancer patients of all histologic subtypes
(37). Taken together, the results indicate a relationship of
high PKP1 (and, to a lesser extent, DSG3) RNA and protein
levels with longer overall survival. Hence, PKP1 and DSG3
expression levels not only serve as specific markers for SCC
but may also have potential prognostic value.
According to our findings, evaluation of CK15 and espe-
cially of DSG3 and PKP1 improves the differential diagnosis
of SCC and AC. However, a potential limitation of these SCC
markers is that membrane-specific positivity is found in
better-differentiated samples that are more readily identifi-
able under the microscope. Nevertheless, they may be espe-
cially useful in samples affected by a major artefact, because
they offer a more objective parameter for evaluating the
degree of differentiation. A further advantage of these
markers is the complete absence of staining in poorly differ-
entiated ACs, observing cytoplasmic and nuclear positivity
only in moderately or well-differentiated ACs. These antibod-
ies could possibly be used in a cocktail, with the consequent
saving of histological sections. This is an important issue,
given the need for genetic as well as immunohistochemical
analyses in tissue from small biopsies in patients with
lung carcinoma.
Despite the small number of samples analyzed, the step-
wise multivariate logistic regression model showed that the
combination of markers CK5/6, p63, and PKP1 in membrane
gave a percentage correct classification of 96.2% overall
(94.6% of AC and 97.6% of SCC), being the best immunohis-
tochemical marker panel to distinguish between SCC and AC.
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